2007•Zhongguo xunhuan zazhiRequires access
Peroxisome Proliferator Activated Receptor-γ Agonists Improves Arterial Stiffness in Type 2 Diabetic Patients With Coronary Artery Disease
Fuchun Zhang
Open publisher page 0 citations
Abstract
Objective:Arterial stiffness is an independent risk factor for cardiovascular events in diabetic patients,and it may be as- sessed by measuring of pulse wave velocity(PWV).We investigated the degrees of arterial stiffness in diabetic patients with coro- nary artery disease and assessed the effect of peroxisome proliferator activated receptor-γ(PPAR-γ)agonist rosiglitazone on arteri- al stiffness levels and its potential mechanism in type 2 diabetes with coronary artery disease patients. Methods:All 46 patients underwent coronary angiography.The patients were randomly divided into two groups:the control (n = 20)and rosiglitazone treatment(n = 26).They received 4 mg rosiglitazone daily for 12 weeks.All patients received meas- urement of PWV before and 12 weeks after treatment.The levels of metabolism parameters including fasting insulin,and high sen- sitivity C-reactive protein(hsCRP)were determined.The statistieal data were analyzed. Results:The value of PWV in the rosiglitazone group was significantly reduced(from 1624±251.9 cm/s to 1438± 217.3 cm/s)(t =2.851,P0.01),compared with the controls 1.2 week after treatment(1 438±217.3 cm/s vs 1 696± 184.1 cm/s,t=4.26,P0.01).PWV levels in the control group showed no difference from baseline levels 12 weeks after treatment.Plasma high sensitivity C-reactive protein levels were significantly decreased in the rosiglitazone group compared with controls 12 week after treatment(0.71±0.10 mg/1 vs 1.25±0.24 rag/L,P0.05).The decrease of hsCRP was correlated linearly with the improvement of HOMA-IR after treatment with PPAR-γ,agonist(r = 0.48,P0.05). Conclusion:Rosiglitazone treatment may significantly decrease arterial stiffness.These results indicate that PPAR-γ agonist may play an important role in preventing arteriosclerosis by normalizing metabolic disorders and depressing chronic inflammation in type 2 diabetic patients with serious vascular damage.